{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT04278417_CONDOR\\NCT04278417_CONDOR_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "All Enrolled Set",
        "text": "The All Enrolled Set includes all subjects who have signed informed consent and are assigned subject numbers.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "All Enrolled",
        "populationDescription": "The All Enrolled Set includes all subjects who have signed informed consent and are assigned subject numbers.",
        "criteria": "Signed informed consent AND assigned subject number"
      },
      {
        "id": "pop_2",
        "name": "Randomized Set",
        "text": "The Randomized Set will consist of all randomized subjects. Subjects are considered randomized when they have been deemed eligible for randomization by the investigator and given a randomization number. Subjects who were randomized but did not receive any study treatment at baseline and discontinued study per subject decision will be classified as screen failures.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Randomized",
        "populationDescription": "The Randomized Set will consist of all randomized subjects. Subjects are considered randomized when they have been deemed eligible for randomization by the investigator and given a randomization number. Subjects who were randomized but did not receive any study treatment at baseline and discontinued study per subject decision will be classified as screen failures.",
        "criteria": "Deemed eligible AND assigned randomization number"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) comprises all randomized subjects who receive at least one study treatment. Subjects in the FAS will be analyzed according to the treatment assigned to them at randomization.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) comprises all randomized subjects who receive at least one study treatment. Subjects in the FAS will be analyzed according to the treatment assigned to them at randomization.",
        "criteria": "Randomized AND received >=1 study treatment"
      },
      {
        "id": "pop_4",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set (SAF) includes all subjects who receive at least one study treatment. Subjects in the SAF will be analyzed according to the actual study treatment they received, where treatment received is defined as the randomized/assigned treatment if the subject took at least one dose of that treatment, or the first treatment received if the randomized/assigned treatment was never received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set (SAF) includes all subjects who receive at least one study treatment. Subjects in the SAF will be analyzed according to the actual study treatment they received, where treatment received is defined as the randomized/assigned treatment if the subject took at least one dose of that treatment, or the first treatment received if the randomized/assigned treatment was never received.",
        "criteria": "Received >=1 study treatment"
      },
      {
        "id": "pop_5",
        "name": "Per Protocol Set",
        "text": "PPS is a subset of the FAS and will exclude or censor data from subjects with important protocol deviations (PDs) and analysis restrictions (ARs) that are expected to majorly affect the validity of the assessment of efficacy at Week 54.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PPS",
        "populationDescription": "PPS is a subset of the FAS and will exclude or censor data from subjects with important protocol deviations (PDs) and analysis restrictions (ARs) that are expected to majorly affect the validity of the assessment of efficacy at Week 54.",
        "criteria": "Subset of FAS AND no important protocol deviations/analysis restrictions affecting efficacy validity"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Age category (<55, >=55 years)"
      },
      {
        "id": "char_2",
        "name": "Sex",
        "code": "SEX",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Male or female"
      },
      {
        "id": "char_3",
        "name": "Baseline BCVA",
        "code": "BASELINE_BCVA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline BCVA",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Best corrected visual acuity categories (<=75, >75 letters)"
      },
      {
        "id": "char_4",
        "name": "Diabetes type",
        "code": "DIABETES_TYPE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Diabetes type",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Type 1 or Type 2"
      },
      {
        "id": "char_5",
        "name": "Baseline HbA1c",
        "code": "BASELINE_HBA1C",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline HbA1c",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Glycosylated hemoglobin A1c categories (<7.5, >=7.5%)"
      },
      {
        "id": "char_6",
        "name": "Baseline DR severity",
        "code": "BASELINE_DR_SEVERITY",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline DR severity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "NPDR, Mild or moderate PDR, High-risk PDR or worse, Ungradable as assessed by CRC"
      },
      {
        "id": "char_7",
        "name": "Region",
        "code": "REGION",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Region",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "US and Canada, East Asia, Other"
      },
      {
        "id": "char_8",
        "name": "Prior anti-VEGF treatment",
        "code": "PRIOR_ANTI-VEGF_TREA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior anti-VEGF treatment",
        "dataType": "Boolean",
        "instanceType": "Characteristic",
        "description": "Prior anti-VEGF treatment in the study eye (yes, no)"
      },
      {
        "id": "char_9",
        "name": "Baseline CSFT",
        "code": "BASELINE_CSFT",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline CSFT",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Central subfield thickness (<280, >=280 um) as assessed by CRC"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 9
    }
  }
}